

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office-Address: COMMISSIONER FOR PATENTS P.O. Bex 1450 Alexandria, Viginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/910,681	07/20/2001	Gregory R.D. Evans	UTSC:646US	2530
	7590 07/16/2003			
FULBRIGHT & JAWORSKI L.L.P. A REGISTERED LIMITED LIABILITY PARTNERSHIP SUITE 2400 600 CONGRESS AVENUE			EXAMINER	
			MARVICH, MARIA	
	AUSTIN, TX 78701		ART UNIT	PAPER NUMBER
			1636	
			DATE MAILED: 07/16/2003	'/

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)			
	Office Action Summers	09/910,681	EVANS ET AL.			
	Office Action Summary	Examiner	Art Unit '			
	TI MANUNA SATE	Maria B Marvich, PhD	1636			
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
	Status					
	1) Responsive to communication(s) filed on					
	2a) This action is <b>FINAL</b> . 2b) ⊠ This action is non-final.					
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
	4)⊠ Claim(s) <u>1-46</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
	5) Claim(s) is/are allowed.					
	6) Claim(s) is/are rejected.					
	7) Claim(s) is/are objected to.					
	8) Claim(s) <u>1-46</u> are subject to restriction and/or election requirement.					
	Application Papers					
	9) The specification is objected to by the Examiner.					
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
	11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
	If approved, corrected drawings are required in reply to this Office action.					
į	12) The oath or declaration is objected to by the Examiner.  Priority under 35 U.S.C. §§ 119 and 120					
	_	adadtu unda 0511000 04404 )	40 40			
	13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
	1.☐ Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the priority documents have been received in this National Stage  3. Copies of the certified copies of the priority documents have been received in this National Stage					
	application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
	a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)						
	1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	PTO-413) Paper No(s) tent Application (PTO-152)			
	S. Patent and Trademark Office TO-326 (Rev. 04-01)  Office Actio	n Summary P	art of Paper No. 11			

Application/Control Number: 09/910,681

Art Unit: 1636

## **DETAILED ACTION**

Claims 1-46 are pending in this application.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-24, drawn to a method for regenerating nerve tissue in vivo, classified in class 435, subclass 455.
- II. Claims 25-46, drawn to an implantable device comprised of a conduit and cells transformed with recombinant DNA, classified in class 435, subclass 325.
   The inventions are distinct each from the other because of the following reasons:

The implantable device of Group II and the methods for regenerating nerve tissue in vivo of Group II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP 806.05 (h)). In the instant case, the implantable device of Group II can be used in materially different methods such as transformation of cells for the purpose of expressing recombinant protein other than a nerve growth factor. Therefore, the inventions of these distinct groups are capable of supporting separate patents.

The searches required for the different groups are not coextensive; a search for art pertaining to methods of nerve regeneration is not coextensive with a search for art pertaining to

Art Unit: 1636

implantable devices comprised of cells containing recombinant DNA. Therefore, restriction for examination purposes as indicated is proper.

These inventions are distinct or the reasons given above and have acquired a separate status in the art as shown by their different classification and their recognized divergent subject matter.

Applicant is reminded that upon cancellation of claims to a non-elected inventions, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria B Marvich, PhD whose telephone number is (703) 605-1207. The examiner can normally be reached on M-F (6:30-3:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, PhD can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 305-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, Zeta Adams, whose telephone number is (703) 305-3291.

PATENT EXAMINER